cephalopathic epilepsy, the results may not be as good. The greatest need in the United States right now is for epileptic agents to treat encephalopathic epilepsies. If zonisamide proved to be a very potent agent for the myoclonic epilepsies of infancy-no matter what their etiology-we would want this to be one of the first indications. If it is a good agent for the myoclonic type of Lennox-Gastaut syndrome, we would want to explore this indication further.
The adverse events, particularly neurotoxicity and hypohidrosis, are of concern. In the open-label multicenter studies, the incidence of hypohidrosis was only 1 in 1008 patients. However, if we look at the number of cases reported in this study 2 plus those in other subsequent studies, the current total is approximately 20.
We can conclude from this paper that zonisamide is an excellent drug for partial and generalized seizures, particularly those of idiopathic origin. It is well tolerated if dosed correctly, and monotherapy is successful. Clearly this is a monotherapeutic drug and it should be used that way whenever possible. We need to further explore the indications and continue to define the adverse effects.
